What is Glyburide Cyclohexyl Isocyanate Sulfonamide?
Glyburide cyclohexyl isocyanate sulfonamide is a chemical compound that appears to be related to the drug glyburide, a medication used to treat type 2 diabetes [1]. The structure suggests it is a derivative or intermediate in the synthesis of glyburide or a related compound [1]. Sulfonamides are a class of drugs that include antibiotics and diuretics, and glyburide itself is a sulfonylurea, a type of oral hypoglycemic agent [2].
What are the Patent Implications for Glyburide Cyclohexyl Isocyanate Sulfonamide?
Patents related to glyburide cyclohexyl isocyanate sulfonamide would likely cover its synthesis, composition of matter, or specific uses. For instance, patents could protect novel methods of producing glyburide or specific crystalline forms that offer improved stability or bioavailability [3]. The existence of such patents would influence the ability of other companies to manufacture or sell the compound or drugs derived from it. Patent expiry dates are critical for generic drug manufacturers looking to enter the market [4].
How Does This Compound Relate to Glyburide's Patent Exclusivity?
If glyburide cyclohexyl isocyanate sulfonamide is an active pharmaceutical ingredient (API) or a key intermediate in the production of glyburide, then patents covering it directly impact glyburide's market exclusivity [3]. Companies may hold patents on the API itself, or on specific manufacturing processes that are difficult to circumvent [4]. The expiration of these patents opens the door for generic versions of glyburide to be produced, potentially lowering drug costs [4].
Who Might Be Interested in Patents for This Compound?
Pharmaceutical companies involved in the research, development, and manufacturing of glyburide or similar antidiabetic medications would be interested in patents covering glyburide cyclohexyl isocyanate sulfonamide [3]. This includes both originators seeking to protect their innovations and generic manufacturers looking to identify opportunities for market entry once patents expire or are successfully challenged [4]. Chemical suppliers who produce intermediates for the pharmaceutical industry might also be involved in patenting novel synthesis routes [3].
What Are the Risks if Patent Protection is Weak or Challenged?
Weak or successfully challenged patent protection for glyburide cyclohexyl isocyanate sulfonamide could lead to premature generic competition for glyburide [4]. This might result in a loss of market share and revenue for the innovator company. Conversely, for generic companies, challenges to existing patents represent a pathway to market entry. Litigation surrounding these patents can be costly and time-consuming for all parties involved [4].
What Are the Next Steps After Patent Expiry for Glyburide?
Following the expiry of relevant patents, including those possibly related to glyburide cyclohexyl isocyanate sulfonamide, generic manufacturers can seek regulatory approval to market their versions of glyburide [4]. This typically involves demonstrating bioequivalence to the reference product. The introduction of generic competition generally leads to a significant reduction in the price of the medication [4].
---
Cited Sources:
1. https://pubchem.ncbi.nlm.nih.gov/compound/Glyburide
2. https://www.ncbi.nlm.nih.gov/books/NBK537273/
3. https://www.uspto.gov/learning-and-resources/glossary/patent-terms
4. https://www.fda.gov/drugs/abbreviated-new-drug-applications-andnas/andabibliography-generic-drug-exclusivity